So this right now is undergoing what we call a Phase III clinical trial, where we’re comparing it to the gold standard, or the most applied technology, but eventually, this this strategy has the potential to be applied to many many different conditions. Right now it is tested in patients with acute leukemia basically and myelodysplastic syndrome, however it could be applied to all patients with hematologic disorders...
So this right now is undergoing what we call a Phase III clinical trial, where we’re comparing it to the gold standard, or the most applied technology, but eventually, this this strategy has the potential to be applied to many many different conditions. Right now it is tested in patients with acute leukemia basically and myelodysplastic syndrome, however it could be applied to all patients with hematologic disorders. And one could even think of applying it to other conditions, even benign conditions for which patients are dying for other non-cancer diseases. So I would say all indications for which stem cell transplant is required could be amenable to this to this strategy.
There still has to be a difference between a donor and recipient, but in most instances, that is the case. With smaller families, we are now faced with the situation where we have to take people that are not perfectly matched, we don’t have the choice that when we are- our parents who had ten kids they, always had a donor available, but these days it’s hard to find somebody that’s compatible. And we’re now even thinking that this may replace unrelated stem cell transplants, so even in the setting of not having anybody in the world registry that’s compatible, we could use strategies of somebody in the family that’s only partially matched. So that is extremely exciting and opens up lots of area for for improvement.
